Gibbs Wealth Management Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Posted by Francis Steltz on Jul 24th, 2026

Gibbs Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 326.2% during the first quarter, HoldingsChannel.com reports. The firm owned 2,306 shares of the biopharmaceutical company’s stock after purchasing an additional 1,765 shares during the quarter. Gibbs Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $1,782,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the stock. WPG Advisers LLC increased its position in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the period. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $29,000. Kemnay Advisory Services Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. Finally, Entrust Financial LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Several articles say Regeneron is expected to beat second-quarter earnings estimates, which could reinforce confidence ahead of the company’s upcoming report. Analysts cited stronger-than-expected fundamentals as a reason for optimism. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Positive Sentiment: Guggenheim reportedly raised its price target on Regeneron to $1,000, a sign that at least one Wall Street firm remains very constructive on the company’s long-term prospects. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
Neutral Sentiment: More pre-earnings coverage suggests analysts expect earnings to decline year over year, so the upcoming report will need to show strong execution to keep sentiment positive. Here’s What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report
Negative Sentiment: A wave of class-action lawsuit alerts and deadline reminders is weighing on sentiment, with allegations tied to disclosures around a Phase III Fianlimab-Libtayo melanoma trial and claims that risks were understated. SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
Negative Sentiment: Multiple law firms are urging investors to join securities fraud litigation, highlighting the earlier sharp share-price drop after the failed Phase 3 trial announcement and keeping legal overhang front and center. REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit – Investors With Losses May Contact Levi & Korsinsky

Regeneron Pharmaceuticals Trading Up 0.1%

Shares of REGN stock opened at $651.91 on Friday. The business has a 50-day moving average price of $636.62 and a two-hundred day moving average price of $714.85. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The firm has a market cap of $68.92 billion, a P/E ratio of 15.88, a price-to-earnings-growth ratio of 1.44 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the company earned $8.22 EPS. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent analyst reports. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. HSBC lowered their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Tuesday. Sanford C. Bernstein decreased their target price on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Finally, TD Cowen upped their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $787.88.

View Our Latest Stock Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.